The new conjugate vaccine MCV4 promises longer duration of immunity and, perhaps, greater clinical efficacy than the polysaccharide vaccine MPSV4. Questions remain about booster doses, vaccinating young children, and safety.
Amanda F. Dempsey, MD, PHD, MPH
Advertisement
Articles by Amanda F. Dempsey, MD, PHD, MPH
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Contemporary Pediatrics
1
FDA grants GEn-1123 rare disease designations for Duchenne muscular dystrophy
2
FDA accepts vedolizumab sBLA for pediatric ulcerative colitis and Crohn's disease
3
ADA 2026 data highlight pediatric outcomes and treatment satisfaction with Afrezza
4
New sunscreen ingredient clears FDA for the first time since the 1990s
5